International Clinical Trial: Prospective, Multicenter, Randomized Controlled Study of Target-Immunotherapy Combined with Local Treatment for Hepatocellular Carcinoma with VP3/4 Portal Vein Tumor Thrombus

Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ChiCTR2600124989) titled 'Prospective, Multicenter, Randomized Controlled Study of Target-Immunotherapy Combined with Local Treatment for Hepatocellular Carcinoma with VP3/4 Portal Vein Tumor Thrombus' on May 20.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Beijing Youan Hospital, Capital Medical University

Condition: Hepatocellular Carcinoma with VP3/4 Portal Vein Tumor Thrombus

Intervention: Trial group 1:Demand-based immune-enhanced TACE therapy (precise embolization via microcatheter superselective catheterization into tumor-feeding arteries targeting 1-3 lesions) combined with targeted immunotherapy ...